m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05191
 [1]
Non-coding RNA miR-381 YTHDF1  lncRNA       miRNA   circRNA Direct Inhibition m6A modification IL18 IL18 YTHDF1 : m6A sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 1 (YTHDF1) READER
 Regulator Info 
m6A Target Interleukin-18 (IL18)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-381 microRNA View Details
Regulated Target YTH domain-containing family protein 1 (YTHDF1) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary Mechanistically, hsa-miR-381 inhibited Interleukin-18 (IL18) translation in LMECs by inhibiting YTHDF1 expression via binding to its 3'-UTR. As expected, YTHDF1 overexpression in LMECs abolished the effects of miR-381-overexpressed exosomes on LMECs injury and Treg cell differentiation.
In-vitro Model
 BMSCs (BMSCs were obtained from the femurs and tibias of 2-3-week-old Sprague-Dawley male rats (Animal Center of Sun Yat-sen University))
In-vivo Model 40 C57BL/6 J male mice (8 weeks old, 20-22 g) obtained from SLAC Experimental Animal Co., Ltd. were randomly assigned into five groups (n = 8): sham, I/R, I/R + Exos, I/R + inhibitor NC-Exos, and I/R + miR-381 inhibitor-Exos.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Interleukin-18 (IL18) 7 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Tadekinig alfa Phase 3 [2]
MOA Inhibitor
External Link
TTD: DF6UP7
 Compound Name GSK-1070806 Phase 2 [3]
Synonyms
Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK
    Click to Show/Hide
External Link
TTD: D06XDS
 Compound Name MEDI-2338 Phase 1 [4]
MOA Modulator
External Link
TTD: D05UCW
 Compound Name Iboctadekin Phase 1 [5]
MOA Modulator
External Link
TTD: D0A8HN
 Compound Name Iboctadekin + Doxil Phase 1 [6]
MOA Modulator
External Link
CID: 5478883
TTD: D0F3PU
 Compound Name Iboctadekin + rituximab Phase 1 [6]
Synonyms
Pepstatin A; 26305-03-3; Pepstatine; Ahpatinin C; UNII-V6Y2T27Q1U; MLS002222329; Iva-Val-Val-Sta-Ala-Sta-OH; V6Y2T27Q1U; CHEMBL296588; 39324-30-6; FAXGPCHRFPCXOO-LXTPJMTPSA-N; C34H63N5O9; NCGC00161670-06; Pepstatin (nonspecific); DSSTox_RID_81334; DSSTox_CID_26095; DSSTox_GSID_46095; CCRIS 3603; Pepstatina; Pepstatinum; Pepstatin (VAN); Ia Quinidine
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0J2VB
 Compound Name IL-18BP Discontinued in Phase 1 [7]
MOA Binder
External Link
TTD: D0I1BQ
References
Ref 1 Bone marrow mesenchymal stem cells-derived exosomal miR-381 alleviates lung ischemia-reperfusion injury by activating Treg differentiation through inhibiting YTHDF1 expression. Cell Signal. 2024 Dec;124:111440. doi: 10.1016/j.cellsig.2024.111440. Epub 2024 Sep 30.
Ref 2 Clinical pipeline report, company report or official report of AB2 Bio.
Ref 3 Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220.
Ref 4 Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 397-412.
Ref 5 Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78.
Ref 6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
Ref 7 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. doi: 10.1517/14728214.13.1.175.